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Abstract
The purpose of this paper is to discuss and analyze the ethical appropriateness of
pulmonary retransplantation as a viable treatment option for end-stage bronchiolitis
obliterans syndrome, commonly referred to as chronic rejection. Lung
transplantation has become a life-saving treatment for patients with advanced lung
disease, yet retransplantation not, for reasons not clearly elucidated. Though
statistics show comparable survival of retransplant to primary transplant recipients,
this is not an option often considered. Through the course of clinical practice, it
became evident that retransplantation had many ethical components that were not
fully investigated as part of the retransplantation process. This paper is to identify
the relevant ethical considerations regarding pulmonary retransplantation.
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Pulmonary Retransplant for a Patient with Bronchiolitis Obliterans Syndrome and
Hepatitis C Viremia: An Ethical Case Analysis

Case Study
A 27-year-old patient underwent bilateral, sequential lung transplantation in March
2002. This patient was critically ill at the time of organ offer: ventilator dependent, in
ICU, profound hemoptysis, and multiple blood transfusions for blood loss due to his
hemoptysis. When a suitable donor organ became available, the patient was transferred
to the transplant center emergently, via mobile ICU.
In the immediate postoperative period, the patient had rising liver functions enzymes
and subsequent testing revealed hepatitis C Viremia (HCV), which was believed to be
transplant-induced. The recipient screened negative for HCV prior to transplant.
Additionally, the outlying hospital reported all blood products given to this patient were
negative for hepatitis viruses.
Approximately 14 months later, the patient had incremental decreases in pulmonary
function testing with concomitant bronchiolitis obliterans on biopsy. Despite multiple
adjunctive therapies, including fundoplication for gastroesophageal reflux (GERD),
Rituxan and photopheresis, bronchiolitis obliterans syndrome (BOS) developed.
Coexisting diagnoses included: hypertension, Cytomegalovirus (CMV) mismatch,
diabetes, and progressive weight loss, currently 106lbs at 72.
In light of aggressive BOS, the transplant team decided to evaluate this patient for
pulmonary retransplantation. Varying ethical dilemmas arose and coincided with
alarming statistics of the success (or relative lack thereof) in pulmonary
retransplantation. The clinical team found themselves divided on this issue, and this
report will examine the clinical, ethical and moral perspectives of this case study.
Clinical Background
Chronic allograft rejection remains the bane of improving long-term outcomes for lung
transplant recipients. BOS is defined as a clinical syndrome of irreversible, progressive
airway obstruction after lung transplantation, caused by the presence of obliterative
bronchiolitis, (Brugire 2003). Bronchiolitis obliterans is a fibrotic process that results in
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the progressive narrowing of the bronchiolar lumen, with concomitant airflow obstruction
(Belperio 2003).
Nearly 50 percent of all pulmonary transplant recipients develop BOS by their fifth
postoperative year (Hertz 2002). The earliest clinically detectable BOS is detectable by
a 10 percent decline, from best postoperative baseline, in Forced Expiratory Volume in
one second (FEV1), and this is called BOS Stage Zero-p (BOS 0-p). Subsequent
decline in FEV1 is assigned into incremental stages, ranging from 1-3 (Estenne 2002).
Suspected risk factors for BOS include acute rejection, medication non-compliance,
Cytomegalovirus infections, organizing pneumonia, older donor age, prolonged
ischemic times, and bacterial/fungal/non-CMV viral infections (Estenne 2002). More
controversial suspected risk factors include airway complications, such as bronchial
anastamotic stenosis and other such complications (Lau 2003); however, these factors
are not convincingly linked to BOS. The Duke University Lung Transplant Group
correlated a relationship between BOS and patients with untreated GERD, as
diagnosed by pH probe, and found that if the GERD was corrected, via fundoplication,
the result was an improvement and/or stabilization of BOS (Davis 2003).
In cardiothoracic transplant, the use of organs infected with HCV is limited to those
patients who are critically ill with precarious likelihood of recovery and stabilization. With
the need for transplant imminent and the scarcity of suitable pulmonary organs, the
utilization of HCV infected organs becomes a medically warranted, needs-based
actuality (Pfau 2000). Cotler (1991) found 17 percent of lung transplant programs have
transplanted HCV (+) lungs into uninfected recipients. By contrast, standard guidelines
for lung transplantation advise against transplantation for patients with active HCV
disease (confirmed with HCV-RNA and biopsy-proven), as fulminant hepatic failure has
been linked to poor outcomes post-transplantation.
The Pulmonary Organ Dilemma
Treatment options for end-stage lung disease have been transformed by the option of
transplantation. However, the availability of acceptable pulmonary organs remains
limited. There are nearly 4000 patients listed for lung transplantation, but 941
transplants were performed in 2000. About 500 patients die while waiting for a
transplant. (Egan 2003). The shortage of usable donors is also a concern because the
lungs are delicate in nature, and most mechanisms of trauma and brain death will more
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so adversely affect the lungs than the solid organs. As such, the quality of the
pulmonary organs is grossly, (sometimes irreversibly), affected (Egan 2003).
There are also greater concerns about the thoracic allocation system, which currently
allocates organs based on ABO compatibility, followed by time accrued on the waiting
list. Following a directive from the Department of Health and Human Services, the
United Network for Organ Sharings (UNOS) Thoracic and Lung Allocation
subcommittees met to develop a new allocations system that would ensure allocation of
this limited organ to those most in need (UNOS 2002).
To ensure fair allocation of thoracic organs, four ethical principles must be considered:
a) Equity (allocation and selection of recipient is made without bias), b) Justice
(providing patients with what is due to them; somewhat righteous in implication; and
suggestive of healthcare practitioners arriving at a decision based on personal values,
moral, etc.), c) Beneficence (to do no harm), and d) Utility (distribution of scarce
resources to ensure optimal outcomes for the many, i.e. efficacy.)
Ethical Analysis of Retransplantation
Though all principles are key, utility prevails because it is an ethical and moral obligation
(Ubel 1993). Organs should be allocated to those patients for whom it will provide the
greatest benefit. However, it is the definition of benefit that remains ill defined. The preexisting therapeutic relationship of the transplant center and their post-operative
patients establishes a fiduciary obligation to that patient. Thus, retransplantation is of
benefit to that patient. Ironically, refusal to consider retransplantation could be a variant
of patient abandonment, which then leads to violation of the ethical principle of nonmalfecience. Conversely, retransplanting one patient when another has not had their
chance with a first transplant can also be abandonment, or possibly even neglect.
Does the transplant team owe the patient for a primary allograft that failed? Is that team
obligated (professionally, morally, or ethically) to provide restitution to the patient (the
second chance retransplant) for his/her suffering? How does the transplant community
justify the expense of retransplantation? And for that matter, is retransplantation even a
cost-effective measure?
As Ubel (1993) states, Decisions to transplant or retransplant would be very hard to
base on a scale of comparative misery - a poignant comment when one takes into
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consideration that the measurement of said misery is subjective and the expression of
which will vary from patient to patient. As health care providers, we must balance our
obligations of efficacious resource allocation with fidelity to care for our patients.
Moreover, while our delivery of health care must ideally be fiscally responsible, we are
duty bound to ensure our treatment for each patient is without regard for financial
incentives or at the expense of patient loyalty. There are instances when our strong
patient advocacy can, in fact, be unjust. Since survival after retransplantation is lower
than after primary transplantation, a guarded approach remains warranted (Novick
1995; Saeed 2001). New data, however, indicates that retransplant candidates who are
ambulatory and not on invasive ventilation have increased survival rates: 64 percent (+/5) at one year, which is comparable to national one-year survival for primary transplants
(Brugire 2003; Novick 1998).
Additionally, Brugires data showed improved survival for patients who were greater than
two years post-transplant (Brugire 2003). Kotloff (2003) urges the transplant community
to maintain equilibrium between the competing goals of maximizing the distribution of a
scarce resource to the greatest number of patients vs. optimizing the outcome of the
individual patient.
One suggestion was to hold retransplant candidates to the same criteria as primary
transplant patients (Novick 1995), which could contribute to improved outcomes posttransplant. Another proposed solution is to establish an annual limit on organs allocated
for retransplantation. Is this a potentially fair solution? While no answer remains
obvious, there is data to suggest long-term viability. Ubel (1995) found while subjects
strongly favored prognosis as the key component in allocation (90 percent favored
organ allocation to patients with a better prognosis), they demonstrated a conviction that
prognosis alone was not enough. Study subjects demonstrated their reluctance to
abandon any group of candidates as if saying that although prognosis is important,
some amount of organs should be set aside to give hope to other candidates, (Ubel
1995).
Societal attitudes on retransplantation are, therefore, not purely utilitarian. There is
concern for efficacy maximization on varying levels to ensure that some benefit is
brought to all potential patients, even those who may be at a disadvantage (Ubel 1995).
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Theories of just allocation remain central to the ethical analysis of retransplantation and
thoracic organ allocation. Resource allocation is defined as the allotment of supplies to
the populace. McKneally (1997) stratified allocation within the context of healthcare:
macro allocation (government distribution); mesoallocation (hospital distribution); and
microallocation (patient distribution.) It is at the level of microallocation that we examine
retransplantation.
Due to the scarcity of donor organs, the wait list mortality for thoracic patients remains
high. Because of this limitation, rationing of resources must utilize justice and fairness,
but what is just and fair remains negotiable. A fair chance is not equivalent to a better
outcome, and this forces the examination of sicker patients to determine their
worthiness. And because patient deaths will occur while waiting for transplant, it is
important to accept the impossibility of a system without wait list mortality.
Bioethical theories on organ allocation are created in an effort to optimize/ensure the
fairest method of distribution for a limited resource, i.e. ensure efficacy as dictated by
utilitarian principles. Historically, allocation criteria included considerations of age, social
worth, financial stability, need, and quality of life (Ubel 1999). And while this does not
favor the primary transplant candidate, neither does it favor the retransplant candidate.
Both patients are of equal need, and the utilitarian analysis would mandate we toss the
proverbial coin to determine allocation (Ubel 1993).
Interestingly, utilitarianism advocates efficacy: transplant the patient with the greater
likelihood of survival. Thus, efficacy remains a morally relevant criterion for distributing
scarce transplant organs, (Ubel 1993). Interestingly, in the Netherlands and Germany,
allocation statutes stipulate: In designating the recipient, account is to be taken of no
other factors than the blood compatibility and histocompatibility of the donor and the
recipient of the organ, the medical urgency for the recipient, and other circumstances
associated with the state of the organ, and also, if these factors are not decisive, then
length of time the recipient must wait, (Price 2000, p.457)
Conclusion
The issue of retransplantation is a complex and intricate decision with various ethical
principles that warrant examination while determining the allocation of an insufficient
supply. Most centers will consider retransplantation on a case-by-case basis and agree
there is an obligation fiduciary, social, and moral - to patients transplanted at their
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center. In this instance, we have a patient who was infected with HCV through the
course of his transplant surgery and now has aggressive BOS warranting earnest
consideration for retransplantation.
This candidate would be declined based on his initial assessment of HCV status;
however, further deliberation is necessary because it is believed the transplant infected
the recipient. The consideration of pulmonary retransplantation is a patient specific
process in which the candidate is re-evaluated as a new referral. Updated diagnostics
studies and measures of functional status, i.e. six minute walk test, cardiopulmonary
exercise test, chest radiographs, and computerized tomography scans, are obtained
and found to be well within acceptable limits for transplant candidacy. Potential
complications and co-morbidities were reviewed, and the patients repeat liver biopsies
show chronic HCV without active disease, fibrosis, or scarring.
The argument for patient fidelity and ethical obligation prevails. The co-morbidity of
HCV, possibly transplant-induced, is an otherwise relative contraindication for lung
transplant and becomes the central focus of this retransplantation decision. The HCV
was left untreated, as research has shown that there is an increased risk of allograft
rejection when treatment with antiviral therapies is initiated. As such, the risk exceeds
the benefit of treatment for HCV in lung transplant recipients (Chan 2004.) The
principles of beneficence (the duty to promote the individual patients best interest),
fairness (equitable distribution of resources), and utility (ensure the best outcomes for
the best recipients) must equilibrate and balance (Biggins 2002).
In addition, transplant teams must consider their reasons for re-transplantation of
individual patients. The fiduciary responsibility must balance with efficacy, and we must
select interventions that will be most effective. Additionally, the use of diseased organs
for transplantation may give rise to the potential for fault liability, possibly even breach of
contract (Price 2000). The fundamental obligation of all transplant programs is to
optimize the well being of their patients through the life-saving measure of organ
transplantation. However, McKneally (1997) believes we must advocate for one’s own
patients but avoid manipulating the system to gain unfair advantage to them.
The Code of Ethics obligates us to promote fair access to health care resources without
losing cost-effectiveness (McKneally 1997). Patient trust remains a key focus, since it is
during times of critical illness that patients are most vulnerable and their trust in the
health care team most indomitable. The resiliency of trust is exemplified in the setting of
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retransplantation what other time would require such conviction and faith in your
transplant team than when contemplating retransplantation? (Hall 1998).
This patient has multiple factors meriting consideration for retransplantation: greater
than two years post-transplant, ambulatory, no invasive ventilation, and no active HCV
disease. The recurrence of BOS is not appreciably greater for retransplant patients
(Laohaburanakit 2003), and retransplantation should be a viable consideration for
patients who have progressive BOS despite rescue measure therapy.
Another consideration is the fiduciary obligation to this patient. Frankly, the unintentional
transplant induced HCV compels the transplant team to consider retransplantation since
it is nearly a breach of contract and thus in violation of the teams intent, which has a
lesser role in arguments of distributive justice and efficacy, to optimize health status.
Moreover, the prior relationship with this patient requires the transplant center to
undertake all efforts within their realm of possibilities to save this patients life. Any
disregard for this patient’s condition is a violation of beneficence, and could result in
death.
In the final analysis, the transplant team must examine the case from multiple
perspectives: ethical, social, moral, and perhaps even financial. We must work in the
interest of our patients, as well as for candidates awaiting primary transplant. In this
case, we have a patient who was dealt an inequitable hand when transplanted HCV
transmission, and progressive BOS. We must remember our ethical obligations to this
patient and trust the data we have on retransplantation to formulate a determination of
survival benefit. The patient is greater than two years post-transplant, free of invasive
ventilation, ambulatory and free of active HCV. The patient also developed BOS after
the first post-operative year.
Additionally, HCV was transplant induced. Diagnostic measures remain within
acceptable limits, and there is no other indication to refuse retransplantation. In this
case, we have decided to move forward with listing the patient for pulmonary
retransplantation, and we hope that our decision will bring about an improved quality of
life for him.
It is my hope that our decision will set precedent and enable a more thoughtful and
cautious analysis of pulmonary retransplantation for patients. If this option is completely
withheld from them, their lives will inevitably and abruptly cease. The implication of a
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rushed death is remarkably unethical. As lung transplant clinicians, we strive to prolong
and improve the quality of our patient’s lives, and we hope that our efforts simplify the
previous complexity of their lives due to progressive, end-stage lung disease. After all,
what is so intricate, so entangled as death? (John Dunne 1628).
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